$VIRX
Viracta Therapeutics, Inc.

2018 Q4 Form 10-Q Financial Statement

#000156459018026884 Filed on November 05, 2018

View on sec.gov

Income Statement

Concept 2018 Q4 2018 Q3 2017 Q4
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.460M $2.690M $2.760M
YoY Change -10.87% -15.41% -29.77%
% of Gross Profit
Research & Development $3.300M $3.590M $3.670M
YoY Change -10.08% -46.89% -23.86%
% of Gross Profit
Depreciation & Amortization $0.00 $10.00K $0.00
YoY Change 0.0%
% of Gross Profit
Operating Expenses $5.760M $6.280M $6.430M
YoY Change -10.42% -36.82% -26.51%
Operating Profit
YoY Change
Interest Expense -$300.0K -$290.0K -$280.0K
YoY Change 7.14% 0.0% -40.43%
% of Operating Profit
Other Income/Expense, Net $60.00K $60.00K $90.00K
YoY Change -33.33% -14.29% 800.0%
Pretax Income -$6.000M -$6.510M -$6.620M
YoY Change -9.37% -35.93% -22.48%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.000M -$6.510M -$6.620M
YoY Change -9.37% -35.93% -22.48%
Net Earnings / Revenue
Basic Earnings Per Share -$0.21
Diluted Earnings Per Share -$5.607M -$6.320M -$0.21
COMMON SHARES
Basic Shares Outstanding 37.42M 31.67M
Diluted Shares Outstanding 31.67M

Balance Sheet

Concept 2018 Q4 2018 Q3 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.70M $20.20M $31.80M
YoY Change -56.92% 61.6% -25.35%
Cash & Equivalents $13.70M $20.16M $26.98M
Short-Term Investments $0.00 $0.00 $4.800M
Other Short-Term Assets $1.500M $1.300M $1.200M
YoY Change 25.0% 0.0% 100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $15.20M $21.50M $32.93M
YoY Change -53.85% 56.93% -23.77%
LONG-TERM ASSETS
Property, Plant & Equipment $11.00K $0.00 $20.00K
YoY Change -45.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $113.0K $108.0K $1.381M
YoY Change -91.82% -91.69%
Total Long-Term Assets $124.0K $86.00K $1.401M
YoY Change -91.15% -93.86%
TOTAL ASSETS
Total Short-Term Assets $15.20M $21.50M $32.93M
Total Long-Term Assets $124.0K $86.00K $1.401M
Total Assets $15.32M $21.59M $34.33M
YoY Change -55.37% 42.95% -20.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.393M $1.277M $1.697M
YoY Change -17.91% -14.87% -10.68%
Accrued Expenses $2.500M $3.700M $3.800M
YoY Change -34.21% 8.82% -25.49%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $7.400M $7.300M $7.200M
YoY Change 2.78% 192.0% 118.18%
Total Short-Term Liabilities $11.32M $12.30M $12.70M
YoY Change -10.84% 66.22% 16.51%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $8.000K $4.000K $112.0K
YoY Change -92.86% -96.0% -33.73%
Total Long-Term Liabilities $8.000K $4.000K $112.0K
YoY Change -92.86% -99.92% -33.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.32M $12.30M $12.70M
Total Long-Term Liabilities $8.000K $4.000K $112.0K
Total Liabilities $11.33M $12.29M $12.79M
YoY Change -11.41% 0.74% -42.39%
SHAREHOLDERS EQUITY
Retained Earnings -$659.5M -$632.9M
YoY Change 4.21%
Common Stock $4.000K $3.000K
YoY Change 33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.993M $9.296M $21.54M
YoY Change
Total Liabilities & Shareholders Equity $15.32M $21.60M $34.33M
YoY Change -55.37% 43.05% -20.52%

Cashflow Statement

Concept 2018 Q4 2018 Q3 2017 Q4
OPERATING ACTIVITIES
Net Income -$6.000M -$6.510M -$6.620M
YoY Change -9.37% -35.93% -22.48%
Depreciation, Depletion And Amortization $0.00 $10.00K $0.00
YoY Change 0.0%
Cash From Operating Activities -$6.500M -$5.450M -$5.350M
YoY Change 21.5% -47.19% -32.87%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $3.400M -$280.0K
YoY Change -100.0% -47.85% -98.26%
Cash From Investing Activities $0.00 $3.400M -$270.0K
YoY Change -100.0% -47.77% -98.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 40.00K 5.180M 24.66M
YoY Change -99.84% 5655.56% -6.31%
NET CHANGE
Cash From Operating Activities -6.500M -5.450M -5.350M
Cash From Investing Activities 0.000 3.400M -270.0K
Cash From Financing Activities 40.00K 5.180M 24.66M
Net Change In Cash -6.460M 3.130M 19.04M
YoY Change -133.93% -184.14% 753.81%
FREE CASH FLOW
Cash From Operating Activities -$6.500M -$5.450M -$5.350M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$6.500M -$5.450M -$5.350M
YoY Change 21.5% -47.19% -32.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1186000
CY2018Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1831000
CY2018Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
112000
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26977000
CY2018Q3 us-gaap Assets
Assets
21586000
CY2018Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
108000
dei Entity Small Business
EntitySmallBusiness
true
CY2018Q3 snss Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
644000
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37421509
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1381000
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1277000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
144000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17898000
us-gaap Profit Loss
ProfitLoss
-20618000
us-gaap Profit Loss
ProfitLoss
-28835000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
217000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
26000
CY2018Q3 us-gaap Liabilities
Liabilities
12290000
CY2018Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
641798000
snss Issuance Of Stock From Vesting Of Restricted Stock Awards
IssuanceOfStockFromVestingOfRestrictedStockAwards
83000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-610000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30786000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
4780000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4780000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
30047000
CY2017Q4 us-gaap Liabilities
Liabilities
12790000
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
20966000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
633436000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
237000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
669000
CY2018Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
snss:LicenseAndOtherRevenueMember
CY2017Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
snss:LicenseAndOtherRevenueMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
snss:LicenseAndOtherRevenueMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
snss:LicenseAndOtherRevenueMember
snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
6040000
snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
8138000
CY2018Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1000
CY2017Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
8000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
7000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
21000
snss Proceeds From Exercise Of Stock Options And Stock Purchase Rights
ProceedsFromExerciseOfStockOptionsAndStockPurchaseRights
263000
snss Proceeds From Exercise Of Stock Options And Stock Purchase Rights
ProceedsFromExerciseOfStockOptionsAndStockPurchaseRights
133000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
2268000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
30021000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
7615000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6303000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
656000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6815000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-109000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8056000
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7947000
us-gaap Stock Issued1
StockIssued1
448000
snss Legal Expenses Accrued As Cost Of Equity Financing
LegalExpensesAccruedAsCostOfEquityFinancing
125000
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
501000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2185000
us-gaap Share Based Compensation
ShareBasedCompensation
2185000
us-gaap Share Based Compensation
ShareBasedCompensation
2424000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2424000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Significant Estimates and Judgments </p> <p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company&#8217;s condensed consolidated financial statements and accompanying notes thereto. Actual results could differ materially from these estimates. Estimates, assumptions and judgments made by management include those related to the valuation of equity and related instruments, debt instruments, revenue recognition, stock-based compensation and clinical trial accounting. </p></div>
CY2018Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
20200000
snss Securities Policy Maturity Limit Period
SecuritiesPolicyMaturityLimitPeriod
P24M
snss Securities Policy Dollar Weighted Average Maturity Limit Period
SecuritiesPolicyDollarWeightedAverageMaturityLimitPeriod
P12M
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15023000
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6507000
CY2017Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
7000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15023000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6507000
CY2018Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
14987000
CY2018Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
14987000
CY2017Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
25250000
CY2017Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
7000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
25243000
CY2017Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
20470000
CY2017Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
20470000
CY2017Q4 snss Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
4780000
CY2017Q4 snss Marketable Securities Gross Unrealized Losses
MarketableSecuritiesGrossUnrealizedLosses
7000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
0
CY2017Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
4773000
CY2018Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2017Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2018Q3 us-gaap Notes Payable
NotesPayable
7500000
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
637000

Files In Submission

Name View Source Status
0001564590-18-026884-index-headers.html Edgar Link pending
0001564590-18-026884-index.html Edgar Link pending
0001564590-18-026884.txt Edgar Link pending
0001564590-18-026884-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
ggpq15tpobzx000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snss-10q_20180930.htm Edgar Link pending
snss-20180930.xml Edgar Link completed
snss-20180930.xsd Edgar Link pending
snss-20180930_cal.xml Edgar Link unprocessable
snss-20180930_def.xml Edgar Link unprocessable
snss-20180930_lab.xml Edgar Link unprocessable
snss-20180930_pre.xml Edgar Link unprocessable
snss-ex311_8.htm Edgar Link pending
snss-ex312_7.htm Edgar Link pending
snss-ex321_9.htm Edgar Link pending